Ruth et al. reported that fractalkine/CX3CL1 and its receptor, CX3CR1, were expressed in RA and a rat adjuvant-induced arthritis model, and soluble fractalkine/CX3CL1 was upregulated in RA synovitis [27]. Here, CX3CL1 is linked to rheumatoid arthritis.